COTA Signs Research Collaboration Agreement With The U.S. Food and Drug Administration

COTA to attend ASCO May 31st – June 4th, 2019 Attending #ASCO19 5/31-6/4? Stop by Booth #2063 to learn how COTA organizes fragmented, often hidden data from the real world to provide a clear view of cancer or schedule a demo with us here: meetus@cotahealthcare.comFind more details about the attending here. Read Full Release

COTA Signs Research Collaboration Agreement With The U.S. Food and Drug Administration COTA, Inc., a leading precision medicine technology company that uses real-world evidence to bring clarity to cancer care, today announced it has signed a two-year Research Collaboration Agreement (RCA) with the U.S. Food and Drug Administration (FDA) Information Exchange and Data Transformation (INFORMED) Program, the Agency's data science and technology incubator supporting regulatory science research. This RCA will establish a study protocol with an initial focus on breast cancer, and will provide the FDA with information on the evolving treatment landscape, including insight on treatment variation within defined subpopulations of patients with the disease. As the project advances, the research may expand to other cancer types and explore disease characteristics, treatment patterns, and patient outcomes for the broader application of precision medicine. Read Full Release

COTA’s Dr. C.K. Wang presents at eyeforpharma’s Health Tech Challenge Read Full Release

COTA Collaborates with Novartis Pharmaceuticals Corporation Cota Healthcare, the leading data and technology platform for value-based precision medicine, today announced the signing of a major, multi-year collaboration with Novartis Pharmaceuticals Corporation to help improve clinical and cost outcomes for breast cancer patients. As part of this agreement, which expands significantly on the previous announced collaboration entered into January 2016, teams from across Novartis Pharmaceuticals Corporation will leverage Cota's research-grade, real-world evidence, web-based analysis and visualization tools, and be supported by Cota's medical, data science, and technology experts. Utilizing the real-world evidence and technology platform supplied by Cota is expected to enable Novartis Pharmaceuticals Corporation to accelerate clinical development of new therapies for breast cancer and identify which patients will benefit most. Read Full Release